The ten-year survival of the BHR Birmingham hip resurfacing Device
Posted April 26, 2012 An independent series D. W. Murray, FRCS, Orthopaedic Surgeon, Professor1 ; G. Grammatopoulos, MRCS, Orthopaedic Registrar1 ; H. Pandit, DPhil, FRCS, Orthopaedic Surgeon1 ; R. Gundle, DPhil, FRCS, Orthopaedic Surgeon2 ; H. S. Gill, DPhil, Lecturer in Orthopaedic Engineering1 ; and P. McLardy-Smith, FRCS, Orthopaedic Surgeon2Abstract Recent events have highlighted the importance of implant design for survival and wear-related complications following metal-on-metal hip resurfacing arthroplasty. The mid-term survival of the most widely used implant, the Birmingham Hip Resurfacing (BHR), has been described by its designers. The aim of this study was to report the ten-year survival and patient-reported functional outcome of the BHR from an independent centre. In this cohort of 554 patients (646 BHRs) with a mean age of 51.9 years (16.5 to 81.5) followed for a mean of eight years (1 to 12), the survival and patient-reported functional outcome depended on gender and the size of the implant. In female hips (n = 267) the ten-year survival was 74% (95% confidence interval (CI) 83 to 91), the ten-year revision rate for pseudotumour was 7%, the mean Oxford hip score (OHS) was 43 (sd 8) and the mean UCLA activity score was 6.4 (sd 2). In male hips (n = 379) the ten-year survival was 95% (95% CI 92.0 to 97.4), the ten-year revision rate for pseudotumour was 1.7%, the mean OHS was 45 (sd 6) and the mean UCLA score was 7.6 (sd 2). In the most demanding subgroup, comprising male patients aged < 50 years treated for primary osteoarthritis, the survival was 99% (95% CI 97 to 100). |